About the Cover
Cover image

Sorafenib, an oncogenic kinase inhibitor, is currently the sole treatment with demonstrated efficacy in liver cancer. In this issue, Galmiche and coworkers report that the proapoptotic protein BAD, a member of the BCL2 family, is a determinant of the cytotoxic effect of sorafenib on liver cancer cells. ABT-737, an inhibitor of proteins of the BCL2 family with a BAD-like reactivity, sensitizes liver cancer cells to the cytotoxic effect of sorafenib. For further details, please see Galmiche and colleagues on page 1116 in this issue.